Proteins and Peptides

20 Feb 2017 Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium
17 Feb 2017 Ascendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients
17 Feb 2017 Capricor Therapeutics Provides Update on Natriuretic Peptide Program
16 Feb 2017 U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
16 Feb 2017 Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
16 Feb 2017 Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 2017
08 Feb 2017 Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
08 Feb 2017 FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
06 Feb 2017 Spyryx Biosciences Announces Successful Completion of Phase 1 Clinical Trial for SPX-101 and Planned Phase 2 Initiation in Cystic Fibrosis During 2017
05 Feb 2017 Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes
01 Feb 2017 Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factors VIIa and IX at EAHAD Annual Congress
31 Jan 2017 Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017
27 Jan 2017 Foresee Pharmaceuticals Announces Top-Line Results from Phase 3 Registration Study in Advanced Prostate Cancer
21 Jan 2017 ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium
21 Jan 2017 Synergy Pharmaceuticals’ TRULANCE™ (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
19 Jan 2017 Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017
18 Jan 2017 BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
18 Jan 2017 Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
18 Jan 2017 SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes
12 Jan 2017 First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
09 Jan 2017 AFSTYLA®, for Haemophilia A, Receives European Commission Approval
09 Jan 2017 Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe
07 Jan 2017 Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome
07 Jan 2017 Okogen Secures Ora® to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis
07 Jan 2017 Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing